News

Bitmine purchased 111,942 Ether last week, its biggest buy so far in 2026, after the token dropped below $2,200.

HYPE reached new highs above $65 following record ETF inflows, futures participation and trading volumes at Hyperliquid exchange. Is $100 next?

NEAR is mirroring a 2023–2024 fractal that preceded a 250% rally, hinting at similar upside in 2026 as privacy coin demand grows.

Everstake said staking made up 60% of disclosed revenue among six Ethereum treasury firms, while loss-making companies posted $1.41 billion in losses.

Ether price eyes a 14% drop to $1,800 as it trades in a classic bearish pattern amid declining total value locked on the Ethereum network.

Bitmine's Tom Lee says the firm could be considered for the Russell 1000, and its stock may get a boost from active and passive fund managers.

Whales withdrew $170 million in XRP from Binance as the price holds a key $1.35-$1.40 accumulation and support zone.

ETH’s rebound toward the whale’s liquidation zone near $2,150 puts its short at risk of over $1 million in potential losses.

The Ethereum Foundation holds less than 1% of all ETH in circulation while other protocol foundations typically hold 10%-50% of their native token's supply, the founder said.

ETH’s bearish chart setup points to a 25% drop toward $1,600, risking over $10 billion in paper losses for BitMine in the coming weeks.

William Mougayar says critics are measuring the Ethereum Foundation by the wrong standard, claiming it was never meant to pump ETH or court institutions.

Binance CEO Richard Teng denied a new WSJ report alleging $850 million in Iran-linked transactions flowed through the exchange to the IRGC.

Ethereum’s dominance in DeFi, stablecoins and staking is strengthening the long-term ETH accumulation thesis, despite it’s 28% price decline in 2026.

NEAR price surges 50% in a week as AI token momentum, Nvidia optimism and network upgrades fuel bullish sentiment.

Repeated bridge exploits and shrinking yields are making institutions question whether DeFi’s risks still justify the returns, says Symbiotic’s Putiatin.